The global war against the coronavirus pandemic continues to wage on while researchers and medical experts seek to find a cure for COVID-19 symptoms. While many believe this is here to stay for an indefinite period, others feel that this too, shall pass.
The number of confirmed cases and death rates only seem to darken our world with over 400,000 confirmed cases in New York, the death toll is now over 31,000, with over 233,000 confirmed cases in Florida, the death toll is now over 4,000, and with over 250,000 confirmed cases in Texas, the death toll is now over 3,000.
And here we are in July 2020 where you can simply add those statistics and drive to find a cure for COVID-19 to our to-do list in the war on cancer and other diseases that still have not seen a cure.
With Florida continuing to make headlines by the day, most recently with one family facing federal charges after allegedly marketing a toxic bleach solution as a cure for multiple ailments, including COVID-19, the timing for our society to come together to help find a cure is essential.
And no, were not kidding. The Florida family (Mark Grennon and his three sons) were charged Wednesday with conspiracy to defraud the United States, conspiracy to violate the Federal Food, Drug and Cosmetic Act, and criminal contempt, according to the Department of Justice.
As for the Florida community, one Tampa business has been conducting the first-in-human clinical study for cutaneous melanoma. Morphogenesis, a clinical-stage company developing novel cell and gene therapies has been making headlines after receiving FDA approval to expand its human clinical trials into two more types of cancer: Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC).
Using its ImmuneFx (IFx) cancer vaccine technology that initiates the power of the immune system on the destruction of tumor cells, Morphogenesis of Tampa will focus its newly FDA approved trials on understanding these two new cancers, which follows in the footsteps of successful human trials on cutaneous melanoma, conducted in cooperation with Moffitt Cancer Center in 2019.
Other MCC and cSCC clinical trial sites across the country include the University of Southern California, the University of Utah, the University of Colorado, and the Dana Farber / Harvard Cancer Center. So why so many trial sites?
Well, according to Morphogenesis CEO Dr. Patricia Lawman, clinical trials need patients, which to qualify, requires an individual having been diagnosed with advanced Merkel or cutaneous squamous cell carcinoma, and having failed or refused other therapies.
As a cell and gene company, the mission from the beginning was to learn from the body and use the bodys building blocks and communication systems to treat chronic disease. Morphogenesis, according to Lawman, was built to identify, isolate and proliferate stem cells and progenitor cells to treat diseases such as diabetes.
With the world united to change the way in which chronic diseases are treated by engaging the innate intelligence of the body, how do companies (on a local level) push for national change?
The ability to genetically modify stem cells to enhance functionality is one aspect of this, but in order to perform a biological function, the stem cells must differentiate into mature cells, e.g. hematopoietic stem cells differentiate into macrophages that perform phagocytic and antigen presentation functions and T cells that kill cancer cells or virally infected cells. Morphogenesis means the evolution of form, which connotes the change for stem cells to these functional cells capable of mitigating chronic disease.
And what this means for our bodies, according to Lawman, is that regardless of the species, our bodies have developed systems that maintain structure and function over a long period of time. When we need to control blood sugar, beta islet cells produce just enough insulin as needed.
Indeed with modern technology, you would think that this is a relatively easy process to control.
There is an exquisite feedback system that regulates this. When things go awry, our best solution has been to provide insulin through pumps that are controlled in part by constant glucose monitors. This one example of where modern technology has tried to solve a problem mimicking how the body works.
However, even providing insulin through a pump cant do what a pancreas can. When it comes to dealing with foreign invaders, the immune system is unequaled. No drug, small molecule or compound can eliminate an invader as well as a fully functional immune system. We can kill cancer cells (while not foreign, they are still invaders) with chemo and radiation, but given the proper assurance, the immune system can eliminate the invader and do it with fewer adverse effects. Almost always, the body performs healing functions better than a synthetic drug or compound.
The companys recent FDA approval to move forward with stage 2 of its clinical trials is a gigantic win for the companys mission. The ability to expand our proof of concept studies from a single skin cancer into other, quite different skin cancers under the same Investigational New Drug (IND) is the next step in the execution of our clinical development plan.
And that starts with Morphogenesis focus on easily accessible tumors.
Since our therapy can be used to treat virtually any type of cancer, we wanted to start out with easily accessible tumors that could be directly injected with our plasmid DNA. The safety data collected from the cutaneous melanoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma Phase 1 trials is a Segway into a Phase 2 skin cancer basket trial testing IFx-Hu2.0 as a monotherapy and in combination with a checkpoint inhibitor.
But anytime there is discussion over stem cell research or breakthroughs in the war on cancer, of course comes naysayers and disbelievers.
One thing that Dr. Lawman has noticed is the bias within scientific circles.
In scientific circles, there has been a bias against simple solutions, including the assumption that to get efficient transfer of genetic material you need viral vectors for all applications. These vectors are complicated to manufacture and use and pose a certain amount of risk to the patients. Plasmid DNA or mRNA, on the other hand, are much safer and are a viable alternative to viruses.
As an example, we inject our plasmid DNA directly into a patients tumor. We get sufficient uptake and expression of our protein to initiate an immune cascade with the effect spreading to multiple tumor antigens. The use of a viral vector in this case would be an unnecessary complication and risk.
Now in todays landscape with COVID-19 putting more pressure on experts to find a cure, Morphogenesis, like any company, is similarly faced with logistical challenges and supply issues.
COVID-19 has certainly affected patient recruitment to our trials. Hopefully, ways will be developed for patients to receive treatment for their terminal diseases even if restrictions continue. Otherwise, the death rate for these patients will be much higher than COVIDs. The biggest challenge for us is the continual process of raising funds that all small biotechs face.
As for ImmuneFx, the companys newest vaccine, we got the exclusive.
Beyond the Phase 2 skin cancer trial, we will be opening trials for head and neck cancer, gastric cancers, cervical cancer and colorectal cancer. The value add here is that successful trial results in multiple types of cancer will substantiate the efficacy and expand our label claims.
But with new products and solutions, come criticism. Lawman added that the one thing that is not usually discussed in such conversations is the importance of the safety profile of a new product.
Some of the new cellular immunotherapies not only come with a hefty price tag, the cost of treating the adverse side effects caused by the therapies can be as much as double the cost of the therapy itself (up to $1.5M total). Some of the newer gene therapies can have a price tag of up to $2M per treatment.
Not only can our plasmid DNA be cost effectively manufactured, it is causing minimal side effects, i.e. what we saw in hundreds of companion animals with naturally occurring cancers is being born out in human patients. Both of these cost saving factors means that ultimately, millions of people will have access to cancer treatment who otherwise would have none.
- Stem Cell Therapy for Treatment of Ocular Disorders - Hindawi - December 27th, 2022
- Researchers find out why some stress is good for you - November 6th, 2022
- Shinya Yamanaka - Wikipedia - October 29th, 2022
- Implanting a Patient's Own Reprogrammed Stem Cells Shows Early Positive ... - October 29th, 2022
- World's first stem cell treatment for spina bifida delivered during fetal surgery - UC Davis Health - October 13th, 2022
- JDRF Announces the Appointment of Qizhi Tang, Ph.D., as Co-Director of The JDRF Center of Excellence in Northern California - PR Newswire - October 13th, 2022
- California court creates regulatory uncertainty over the FDA regulation of stem cell therapies - BioEdge - October 4th, 2022
- Scientists have created a mechanical womb that can grow life in the lab - Inverse - October 4th, 2022
- ISCT: California stem cell ruling is flawed and has inserted regulatory uncertainty into the CGT market - BioPharma-Reporter.com - September 16th, 2022
- Scientists Use Stem Cells to Create Synthetic Mouse Embryos - September 16th, 2022
- UK Equine Research Hall of Fame Inductees Announced - Equi Management - September 16th, 2022
- Cultured meat startup Prolific Machines unveils its Henry Ford approach to cell growth - TechCrunch - September 16th, 2022
- New Stem Cell Therapy Protects Brain Against the Neurological Disorder - Nature World News - September 8th, 2022
- Scientists Are Working on New and Improved Hair Loss Treatments - Gizmodo - September 8th, 2022
- What happens to the brain on prescription steroids? - Medical News Today - September 8th, 2022
- How this scientist uses Legos to explain the power of stem cells - August 30th, 2022
- CIRM Bridges intern researches stem cells to grow kidneys - August 30th, 2022
- Alzheimer's: Could controlling the brain's own clean-up crew help? - Medical News Today - August 22nd, 2022
- Trial to Compare Safety and Efficacy of Novel Cell Therapy to Standard of Care in Patients With Rare Blood Cancers - Curetoday.com - August 5th, 2022
- Medpoint Global was awarded the Best Revolutionary Hair Transplant Center of the Year and continues to follow developments in its field and offer more... - August 5th, 2022
- Cell Culture Media Market Worth $14.64 Billion by 2029 - Exclusive Report by Meticulous Research - GlobeNewswire - August 5th, 2022
- Haifan Lin takes on new role as President of the ISSCR - EurekAlert - July 3rd, 2022
- UCI-led team discovers signaling molecule that potently stimulates hair growth - UCI News - July 3rd, 2022
- Calidi Biotherapeutics Announces Appointment of W.K. Alfred Yung, M.D., to its Medical Advisory Board - Business Wire - July 3rd, 2022
- Organoids reveal similarities between myotonic dystrophy type 1 and Rett syndrome - EurekAlert - July 3rd, 2022
- Our View: Roe reversal hard hit to science - The Durango Herald - July 3rd, 2022
- Connection Map Reveals Changes in the Injured Brain - Technology Networks - June 22nd, 2022
- Scientists Used CRISPR to Trace Every Human Gene to Its Function - Singularity Hub - June 22nd, 2022
- Maike Sander named to lead the Max Delbrck Center - EurekAlert - June 22nd, 2022
- CRISPR-Cas12a Editing Rates Improve with Better Directions to the Nucleus - Genetic Engineering & Biotechnology News - June 22nd, 2022
- UB-led study presents critical step forward in understanding Parkinson's disease and how to treat it - University at Buffalo - June 13th, 2022
- Stem Cells: A Case for the Use of Human Embryos in Scientific Research - June 4th, 2022
- Top Beverly Hills Plastic Surgeon, Dr. John Anastasatos, Explores Cell-Assisted Lipotransfer (CAL) with Breast Augmentation in New Publication -... - June 4th, 2022
- Regenerative Medicine Market To Grow At A CAGR Of 11.27% By 2027, Due To Advancements In Cell Biology, Genomics Research, And Gene-Editing Technology... - June 4th, 2022
- Google Reverses Ban on Ads for All Stem Cell Therapies, Will Allow FDA-Approved Ones - Gizmodo Australia - May 15th, 2022
- Head-To-Head Survey: Jasper Therapeutics (NASDAQ:JSPR) & CytRx (OTCMKTS:CYTR) - Defense World - May 15th, 2022
- Primary Cell Culture Market Mechanical Separation Segment Is Expected To Witness A Lucrative CAGR Of 11.7% Till 2028, Owing To Advancements In... - May 15th, 2022
- Ray Therapeutics Receives $4M in Funding From the California Institute for Regenerative Medicine (CIRM) - BioSpace - May 2nd, 2022
- Predicting the Future of Food - Bon Appetit - May 2nd, 2022
- FDA Grants Direct Biologics Regenerative Medicine Advanced Therapy (RMAT) Designation for the use of ExoFlo in COVID-19 Related ARDS USA - English -... - April 19th, 2022
- Chronic Diseases Is Expected To Have Positive Impact On Stem Cell Characterization Kits Market Demand Bloomingprairieonline - Bloomingprairieonline - April 19th, 2022
- Cleveland Cord Blood Center and Deverra Therapeutics Announce Agreement - Yahoo Finance - April 6th, 2022
- A model that mimics malformation associated with severe epilepsy paves way to novel therapies - EurekAlert - March 25th, 2022
- Stem cell agency: Following the money - and its performance - Capitol Weekly - December 24th, 2021
- Epithelial Cell Culture Media Market to hit US$ 303040.33 thousand by 2028, at 11.4% CAGR: The Insight Partners - Digital Journal - December 24th, 2021
- What is Biohacking? Understanding the Silicon Valley Wellness Trend Youll Hear About in 2022 - SheKnows - December 24th, 2021
- Second Woman Spontaneously Clears HIV: 'We Think More Are Out - Medscape - November 22nd, 2021
- Business Partnership for Development and Commercialization of Medical Device Implant Utilizing MSC2 for the Regeneration of Esophageal Tissue in... - November 22nd, 2021
- Misinformation on stem cell treatments for COVID-19 linked to overhyped science, researchers argue - EurekAlert - October 16th, 2021
- Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in... - October 16th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - WSAW - October 5th, 2021
- BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa - WWNY - October 5th, 2021
- UC Davis and the School of Medicine set new records in research funding - UC Davis Health - August 31st, 2021
- FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum - July 21st, 2021
- Stem cell model reveals how COVID-19 can infect the brain - Study Finds - July 21st, 2021
- Introducing the 3D bioprinted neural tissues with the potential to 'cure' human paralysis - 3D Printing Industry - July 21st, 2021
- Insception Lifebank and Cells for Life Join the Generate Life Sciences Family to Create a Global Platform - Canada NewsWire - June 6th, 2021
- Innovative Regenerative Medicine Therapies Safety Comes First - FDA.gov - June 6th, 2021
- ViaCyte to Present Late-Breaking Data at the American Diabetes Association's 81st Scientific Sessions - PRNewswire - June 6th, 2021
- Viral vector unlikely to be cause of leukemia in gene therapy patient - Science Magazine - March 11th, 2021
- Astrocytes Derived from Patients with Bipolar Disorder Malfunction - UC San Diego Health - March 11th, 2021
- Peer Recognition | The UCSB Current - The UCSB Current - March 11th, 2021
- Stem cells on the ballot - Science Magazine - January 20th, 2021
- Controlling the immune system with 'invisible stem' cells - BioNews - January 20th, 2021
- How a UCSF team is giving Cronutt the sea lion a second chance with neuroscience - University of California - October 20th, 2020
- What Proposition 14 Tells Us About California - The New York Times - October 20th, 2020
- California Proposition 14: Funding medical research that uses stem cells - KTLA - October 20th, 2020
- Technology to natures rescue - The Hindu - October 20th, 2020
- What You Need to Know About Prop 14, The Stem Cell Research Bond (Transcript) - KQED - October 5th, 2020
- UC Davis Engineers Lead $36M Effort to Improve Recovery From Spinal Cord Injuries - UC Davis - October 5th, 2020
- Dust off the crystal ball: It's time for STAT's 2020 Nobel Prize predictions - STAT - October 5th, 2020
- Stem Cells Offer Hope of Treatment for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS) - HospiMedica - September 15th, 2020
- David Shavelle, MD, Named Medical Director of Adult Cardiology for the MemorialCare Heart & Vascular Institute at Long Beach Medical Center -... - September 15th, 2020
- Seeing the eye like never before | Newsroom - UW Medicine Newsroom - September 15th, 2020
- Gore partners with San Diego company on cell delivery system with potential to treat Type 1 diabetes - delawarebusinessnow.com - August 12th, 2020
- Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19 - PRNewswire - August 12th, 2020
- Meet The 12 Next-Gen Food Techs Transforming The Future Of Protein - Green Queen Media - August 12th, 2020
- BeyondSpring Initiates Expanded Access Program with Plinabulin for Patients Suffering from CIN in the US - BioSpace - August 12th, 2020
- BCLI: Phase 3 ALS Data Expected by the End of November 2020 - Yahoo Finance - August 12th, 2020
- Impact of COVID 19 pandemic on Stem Cell Characterization and Analysis Tools Market Structure and Its Segmentation - 3rd Watch News - July 1st, 2020